Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer: Does proper lymphadenectomy improve survival? LYTEC Trial & AGO-ECLAT trial Is there a need for adjuvant chemotherapy in node negative high-risk early stage patients?
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Adjuvant Endometrial Cancer Trial Mansoor@rh.regionh.dk
ENGOT-NESTEC: answer 4 major questions in the management of endometrial cancer:NEtwork STudy in Endometrial Cancer
under the ENGOT umbrella and in cooperation with the Mayo clinic.
Clinically presumed: FIGO IB-II any histo type, FIGO I A G3 endometroid, FIGO IA/B histo type II
Mayo trial (Dowdy, Mariani)
AGO ECLAT trial (Emons)
NSGO trial (Hogberg)
AGO/NOGGO trial (Sehouli)
DGCG trial (Mirza)
No bulky LN
FIGO III not Ro and pos. LN or cytology only; FIGO IV
Recurrent FIGO I/II
+ extra LN disease
without extra LN disease
+ mTOR inhibitor